UBS Group’s Syneos Health, Inc. Class A Common Stock SYNH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-269,403
| Closed | -$11.4M | – | 10233 |
|
|
2023
Q2 | $11.4M | Buy |
269,403
+265,679
| +7,134% | +$10.7M | ﹤0.01% | 1875 |
|
|
2023
Q1 | $133K | Sell |
3,724
-4,084
| -52% | -$148K | ﹤0.01% | 5691 |
|
|
2022
Q4 | $286K | Sell |
7,808
-2,783
| -26% | -$110K | ﹤0.01% | 5166 |
|
|
2022
Q3 | $499K | Buy |
10,591
+4,858
| +85% | +$314K | ﹤0.01% | 4346 |
|
|
2022
Q2 | $411K | Sell |
5,733
-3,028
| -35% | -$221K | ﹤0.01% | 4398 |
|
|
2022
Q1 | $710K | Sell |
8,761
-30,772
| -78% | -$2.6M | ﹤0.01% | 4426 |
|
|
2021
Q4 | $4.06M | Sell |
39,533
-10,478
| -21% | -$1.01M | ﹤0.01% | 3057 |
|
|
2021
Q3 | $4.38M | Sell |
50,011
-25,436
| -34% | -$2.3M | ﹤0.01% | 2810 |
|
|
2021
Q2 | $6.75M | Buy |
75,447
+37,530
| +99% | +$3.17M | ﹤0.01% | 2388 |
|
|
2021
Q1 | $2.88M | Buy |
37,917
+1,192
| +3% | +$89.9K | ﹤0.01% | 3188 |
|
|
2020
Q4 | $2.5M | Sell |
36,725
-139,240
| -79% | -$8.68M | ﹤0.01% | 3186 |
|
|
2020
Q3 | $9.35M | Buy |
175,965
+56,555
| +47% | +$3.37M | ﹤0.01% | 1690 |
|
|
2020
Q2 | $6.96M | Buy |
119,410
+64,384
| +117% | +$3.46M | ﹤0.01% | 1798 |
|
|
2020
Q1 | $2.17M | Sell |
55,026
-99,756
| -64% | -$5.83M | ﹤0.01% | 2689 |
|
|
2019
Q4 | $9.21M | Buy |
154,782
+66,296
| +75% | +$3.56M | ﹤0.01% | 2031 |
|
|
2019
Q3 | $4.71M | Buy |
88,486
+69,767
| +373% | +$3.58M | ﹤0.01% | 2439 |
|
|
2019
Q2 | $957K | Buy |
18,719
+12,907
| +222% | +$601K | ﹤0.01% | 3786 |
|
|
2019
Q1 | $300K | Sell |
5,812
-6,687
| -54% | -$324K | ﹤0.01% | 4372 |
|
|
2018
Q4 | $492K | Buy |
12,499
+8,432
| +207% | +$392K | ﹤0.01% | 4282 |
|
|
2018
Q3 | $210K | Sell |
4,067
-815
| -17% | -$39.9K | ﹤0.01% | 5019 |
|
|
2018
Q2 | $228K | Sell |
4,882
-2,444
| -33% | -$101K | ﹤0.01% | 4847 |
|
|
2018
Q1 | $260K | Buy |
7,326
+2,187
| +43% | +$85.7K | ﹤0.01% | 4611 |
|
|
2017
Q4 | $224K | Sell |
5,139
-22,590
| -81% | -$1.06M | ﹤0.01% | 4835 |
|
|
2017
Q3 | $1.45M | Buy |
27,729
+20,412
| +279% | +$1.14M | ﹤0.01% | 3391 |
|
|
2017
Q2 | $428K | Buy |
7,317
+3,567
| +95% | +$185K | ﹤0.01% | 4223 |
|
|
2017
Q1 | $172K | Sell |
3,750
-1,201
| -24% | -$59.8K | ﹤0.01% | 4732 |
|
|
2016
Q4 | $261K | Buy |
4,951
+1,337
| +37% | +$64.7K | ﹤0.01% | 4602 |
|
|
2016
Q3 | $161K | Buy |
3,614
+338
| +10% | +$14.7K | ﹤0.01% | 4693 |
|
|
2016
Q2 | $125K | Buy |
3,276
+2,267
| +225% | +$99.6K | ﹤0.01% | 4880 |
|
|
2016
Q1 | $42K | Sell |
1,009
-44,248
| -98% | -$1.82M | ﹤0.01% | 5631 |
|
|
2015
Q4 | $2.19M | Buy |
45,257
+44,548
| +6,283% | +$1.98M | ﹤0.01% | 2704 |
|
|
2015
Q3 | $28K | Sell |
709
-9,924
| -93% | -$433K | ﹤0.01% | 6370 |
|
|
2015
Q2 | $427K | Buy |
10,633
+5,120
| +93% | +$177K | ﹤0.01% | 4259 |
|
|
2015
Q1 | $180K | Buy |
5,513
+3,239
| +142% | +$89.5K | ﹤0.01% | 4968 |
|
|
2014
Q4 | $59K | Buy |
+2,274
| New | +$54.1K | ﹤0.01% | 6282 |
|
Other funds holding SYNH
IA
BTI
CFB
HNB
UBS Group's SYNH Position: Q3 2023 in Review
UBS Group sold out of Syneos Health, Inc. Class A Common Stock (SYNH) in Q3 2023, closing a stake of 269,403 shares — an estimated $11.4M sold.
UBS Group first reported a position in SYNH in Q4 2014 and held it in 35 quarters. The position peaked at $11.4M in Q2 2023. 10 funds tracked by Wall St. Rank hold SYNH as of Q3 2023.
- UBS Group reported no remaining Syneos Health, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- UBS Group sold 269,403 Syneos Health, Inc. Class A Common Stock shares in Q3 2023, an estimated $11.4M.
- UBS Group first reported a position in Syneos Health, Inc. Class A Common Stock in Q4 2014 and held it in 35 quarters.
- UBS Group's Syneos Health, Inc. Class A Common Stock position peaked at $11.4M in Q2 2023.
- 10 funds tracked by Wall St. Rank held Syneos Health, Inc. Class A Common Stock as of Q3 2023.
Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.